Enter patient or subject data to compute an AI-powered addiction risk score
⚠️ This tool is for research and educational purposes only. Not validated for clinical diagnosis.
AI reasoning is grounded in published COGA / NIAAA neuroscience — not trained on restricted dbGaP EEG recordings.
Subject profile
Cognitive performance
From neuropsychological battery or behavioral task results
Reaction time (ms)Norm: 250–380 ms
320 ms
Task accuracy (%)Norm: 85–95%
88%
Commission errors (%)Norm: <12%
10%
Inhibitory control scoreHigher = better. Norm: 70–90
80
Working memory scoreHigher = better. Norm: 75–90
82
Self-report / clinical scales
Impulsivity (BIS-11 style)Higher = more impulsive. Norm: 30–45
38
Reward sensitivityHigher = more sensitive. Norm: 45–60
52
AUDIT score0–7 low · 8–15 hazardous · 16+ harmful
4
EEG spectral power
Values from your EEG analysis software (MNE-Python, EEGLAB, Brainstorm, etc.)
Fz
Cz
Pz
F3
F4
Simulated waveform preview — updates as you adjust band powers
Most accurate mode: combines EEG neurophysiology with behavioral assessment
EEG biomarkers
P300 amplitudeμV
12 μV
Beta powerμV²/Hz
8 μV²
Theta coherence
68
Behavioral markers
ImpulsivityBIS-11 style
38
Reaction timems
320 ms
AUDIT score
4
—
risk score / 100
—
Severity estimate
—
Biomarker flags
Feature relevance
AI clinical interpretation
Grounded in COGA/NIAAA evidence · Not a medical diagnosis
Analyzing inputs...
Session history
No analyses run yet.
About this system
Architecture, evidence base, and intended use
Evidence base
This tool is grounded in findings from the Collaborative Study on the Genetics of Alcoholism (COGA) — a multi-site longitudinal study funded by NIAAA spanning 30+ years. Key biomarkers used:
P300 amplitude — reduced in individuals with AUD and their at-risk offspring before first drink (Begleiter et al. 1984; Jones et al. 2006)
Beta power — elevated frontal beta linked to GABRA2 on chromosome 4, associated with AUD (Rangaswamy et al. 2002, 2004; Porjesz et al. 2002)
Theta coherence — fronto-parietal theta synchrony reduced in AUD; CHRM2 on chromosome 7 implicated (Porjesz & Rangaswamy 2007)
Delta/theta power — weaker during oddball task in AUD and high-risk relatives (Jones et al. 2006)
Machine learning — EEG measures used to predict AUD development (Kinreich et al. 2021)
Simulates COGA-style EEG epochs (19 channels, 256 Hz), behavioral scores, and clinical labels. Replace simulate_coga_dataset() with your real dbGaP download.
70/15/15 train/val/test split · 5-fold stratified cross-validation · data augmentation (noise injection) · model serialized to model.pkl.
6
Evaluation — evaluate.py
ROC curve, confusion matrix, CV band plot, severity scatter, attention-weight heatmap (channel × band), feature importance bars. All saved to outputs/dashboard.png.
Clinical applications
Early risk detection — P300 attenuation is detectable in adolescents before first drink; enables preventive intervention in high-risk families
Disorder differentiation — extend label set to AUD / ADHD / MDD / Healthy for multiclass classification of overlapping cognitive phenotypes
Treatment monitoring — run severity regression longitudinally to track whether a patient's neural profile is converging toward the healthy distribution during intervention
Genetic risk stratification — integrate polygenic risk scores (GABRA2, CHRM2 variants) as additional features
# Run full pipeline (data → train → evaluate → dashboard)
cd neuro_addiction_ai
python main.py
# Outputs saved to neuro_addiction_ai/outputs/
# model.pkl — serialized trained model
# results.json — all metrics and feature importances
# dashboard.png — full evaluation visualization
Important limitations
The web app AI reasoning uses Claude's knowledge of COGA/NIAAA literature — it is not a model trained on the actual COGA EEG recordings (those require NIH dbGaP data access approval)
The Python pipeline trains on simulated data that replicates COGA statistical signatures — performance on real data will differ
Perfect cross-validation scores (AUC=1.0) are expected on clean simulated data and are not representative of real-world performance
This tool must not be used for clinical diagnosis or treatment decisions